GIP

Global Weight Loss Drugs Markets Report 2023-2024 & 2029 - The Emergence of GLP-1 and GIP, Unmet Market Needs and Emerging Product Pipeline - ResearchAndMarkets.com

Retrieved on: 
Vendredi, avril 26, 2024
Health, Fitness & Nutrition, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Online, Conditional sentence, Market, Semaglutide, Sale, Investment, Social media, Injection, Weight gain, Huadong Medicine, Safety, Risk, Plasma protein binding, CDC, Underweight, Alli, OTC, Overweight, Eli Lilly, GSK plc, Diabetes, Weight loss, Research, Liraglutide, USFDA, Appetite, Success, Roche, Obesity, Culture, Novo Nordisk, Distribution, Patient, Powder, Metabolism, Marketing, GIP, Cancer, COVID-19, Pharmacy, Growth, Prevalence, Pharmaceutical industry

The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.

Key Points: 
  • The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.
  • The global weight loss drugs market is expected to grow at a CAGR of 49.85% over the years 2024-2029.
  • The weight loss drugs market in the Asia Pacific is expected to grow significantly during the forecasted period.
  • Offline distribution channels, comprising brick-and-mortar pharmacies, clinics, and healthcare facilities, dominated the global weight loss drugs market in 2023.

Mouser Electronics Sponsors Ten80 STEM Challenge to Empower Future Engineers and Innovators

Retrieved on: 
Lundi, avril 22, 2024
EV, Electric Vehicles, Sports, Hardware, Motor Sports, Technology, Autonomous Driving, Vehicles, Other Education, Automotive, Semiconductor, Education, Engineering, Manufacturing, Analog Devices, UAV, News, Mouser, Marketing, Entrepreneurship, Student, Curriculum, Automation, Science, Electronics, Area studies, NPI, Multimedia, GIP, ADI, National Science Foundation, Organization, Management

Mouser Electronics , Inc., the New Product Introduction (NPI) leader™ empowering innovation, proudly announces that it will be a sponsor of the Ten80 Education STEM Challenge National Finals, April 26–27, 2024 at the Charlotte Motor Speedway in Concord, NC.

Key Points: 
  • Mouser Electronics , Inc., the New Product Introduction (NPI) leader™ empowering innovation, proudly announces that it will be a sponsor of the Ten80 Education STEM Challenge National Finals, April 26–27, 2024 at the Charlotte Motor Speedway in Concord, NC.
  • View the full release here: https://www.businesswire.com/news/home/20240422047610/en/
    The Ten80 STEM Challenge Finals are April 26–27 at the Charlotte Motor Speedway in Concord, NC.
  • “Mouser is excited to continue our support of Ten80 Education and its highly interactive STEM educational initiatives for students,” said Kevin Hess, Mouser’s Senior Vice President of Marketing.
  • As a global authorized distributor, Mouser offers the widest selection of the newest semiconductors, electronic components and industrial automation products.

GIP Australia Fund II Announces A$4.0 Billion Final Closing

Retrieved on: 
Mardi, avril 9, 2024
Banking, Asset Management, Professional Services, Finance, GIPA, GIP, Global Infrastructure Partners, Investment, Fund, Renewable energy

Global Infrastructure Partners (“GIP”), a leading infrastructure investor, announced today that the GIP Australia Fund II (“GIPA II” or “the Fund”) has completed fundraising with aggregate committed capital of A$4.0 billion, at the upper end of the target A$3.0 – 4.0 billion range.

Key Points: 
  • Global Infrastructure Partners (“GIP”), a leading infrastructure investor, announced today that the GIP Australia Fund II (“GIPA II” or “the Fund”) has completed fundraising with aggregate committed capital of A$4.0 billion, at the upper end of the target A$3.0 – 4.0 billion range.
  • A number of these investors also participated in the GIP Australia Fund I and account for nearly half of GIPA II’s commitments.
  • GIPA II is a dedicated Australasia-focused open-ended fund that extends GIP’s Flagship equity strategy to opportunities across the region.
  • “Australia has always been an important market for GIP and our Australia Fund Platforms are an important and natural extension of our global reach.

EQS-News: Søren Skou appointed as Chair of the Advisory Board of Skyborn Renewables

Retrieved on: 
Mercredi, avril 10, 2024
Partnership, GIP, Global Infrastructure Partners, Advisory board, Growth, Acquisition

Søren Skou, the former Chief Executive Officer (CEO) of A.P.

Key Points: 
  • Søren Skou, the former Chief Executive Officer (CEO) of A.P.
  • Moller-Maersk (“Maersk”), has joined Skyborn Renewables (“Skyborn”) as Chair of the Advisory Board.
  • “We are delighted to welcome Søren to Skyborn.
  • “I am very pleased to join Skyborn,” said Skou.

EQS-News: Skyborn Announces Leadership Transition

Retrieved on: 
Mercredi, avril 10, 2024
Shell plc, Advisory board, Growth, Entrepreneurship, Diesel exhaust fluid, Wind, Carbon, Happiness, E.ON, GIP, Marketing

Thomas will continue in an advisory capacity, serving as a counselor to both the Advisory Board and Patrick to enable an effective transition for Skyborn.

Key Points: 
  • Thomas will continue in an advisory capacity, serving as a counselor to both the Advisory Board and Patrick to enable an effective transition for Skyborn.
  • "We thank Thomas for his leadership in navigating the challenges faced by Skyborn and its offshore wind developer peers over the past year, in building Skyborn into a stronger, more resilient company and for his support in ensuring a seamless transition.
  • Patrick Lammers brings strong commercial, customer, and digital experience to Skyborn, as it continues to establish itself as a leader for offshore wind’s role in the energy transition.
  • I look forward to transitioning the leadership of Skyborn to Patrick, who I am confident will continue the growth and development of Skyborn into one of the world’s leading offshore wind platforms.”

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Retrieved on: 
Mercredi, mars 20, 2024
Research, Teriparatide, Conference call, Conference, Obesity, Serum, SAN, Weight loss, Female, Adalimumab, Volunteering, Human, Society, Osteoporosis, Workforce, Expansion, Growth, GIP, Business operations, GLP, Animal, HC, Pharmaceutical industry

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • ET / 1:30 p.m. PT -
    SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
  • In February 2024, Rani announced RT-111 achieved high bioavailability and was well-tolerated, with no serious adverse events in humans, in a Phase 1 study.
  • In December 2023, Rani announced preclinical data demonstrating the transenteric delivery of an incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study.
  • In October 2023, Rani announced preclinical data from a 60-day, repeat oral-administration GLP safety study of the RaniPill capsule in healthy animals.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Vendredi, mars 8, 2024
Molecule, Therapy, IPF, SAN, Research, Investment, Obesity, Apelin, Idiopathic pulmonary fibrosis, Growth, GIPR, GIP, A1C, Interim, Safety, GPCR, G&A, Glycated hemoglobin, Pharmaceutical industry

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
  • This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

Global Infrastructure Partners Announces Total $2.1 Billion Final Closing of Its Inaugural Emerging Markets Fund

Retrieved on: 
Mardi, mars 5, 2024
Banking, Asset Management, Professional Services, Finance, Market, Investment, Emerging market, GIP, Global Infrastructure Partners, Fund, Insurance, Pension fund

Global Infrastructure Partners (GIP), a leading infrastructure investor, announced today that GIP Emerging Markets Fund I (“GIP EM” or “the Fund”) has completed fundraising for aggregate committed capital of more than $2.1 billion.

Key Points: 
  • Global Infrastructure Partners (GIP), a leading infrastructure investor, announced today that GIP Emerging Markets Fund I (“GIP EM” or “the Fund”) has completed fundraising for aggregate committed capital of more than $2.1 billion.
  • The Fund garnered significant support from GIP’s existing investor base while also attracting new investors with a specific interest in emerging markets infrastructure.
  • GIP Emerging Markets Fund I is a dedicated emerging markets-focused fund that extends GIP’s Flagship equity strategy to opportunities in 11 Target Countries in Asia and Latin America.
  • “We are extremely gratified by the confidence that EM Fund investors have placed in us,” said James Amine, GIP Partner and Head of Emerging Markets.

Eversource Energy Announces Pathway to Fully Exit its Offshore Wind Investments Pursuant to Agreement with Global Infrastructure Partners to Sell Revolution Wind and South Fork Wind Projects

Retrieved on: 
Mardi, février 13, 2024
Alternative Energy, Energy, Utilities, Oil, Gas, Acquisition, Public policy, Weather, Investment, Natural gas, Innovation system, Confidentiality, Growth, Terrorism, Sale, GIP, Wind, Federal Energy Regulatory Commission, Risk, Climate change, Public expenditure, Economics, Goldman Sachs, Delays, Ropes & Gray, Partnership, Renewable energy

Eversource Energy (NYSE: ES) (“Eversource”) today announced it has executed a definitive agreement to sell its 50 percent ownership share in South Fork Wind and Revolution Wind to Global Infrastructure Partners (GIP).

Key Points: 
  • Eversource Energy (NYSE: ES) (“Eversource”) today announced it has executed a definitive agreement to sell its 50 percent ownership share in South Fork Wind and Revolution Wind to Global Infrastructure Partners (GIP).
  • The agreement covers Eversource’s 50 percent share in the 132-megawatt South Fork Wind project and the 704-megawatt Revolution Wind project.
  • Eversource is expected to enter into a separate construction management agreement as a contractor to Revolution Wind to complete the onshore work that is currently underway.
  • Eversource will maintain its previously announced tax equity investment in South Fork Wind.

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Retrieved on: 
Mardi, février 6, 2024
Marker beacon, Manuscript, Bioinformatics, Peptide, Weill Cornell Medicine, Research, Genetic variation, Nature Communications, Cardiovascular disease, Gene, Nanoparticle, Proteome, Metabolomics, GIP, Drug discovery, Mass spectrometry, Protein, Medicine, Biophysics, Proteomics, Physiology, Plasma

REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer’s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci (pQTL) studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution.

Key Points: 
  • The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV.
  • Most MS-PAVs were aligned with known genetic markers (cis-pQTLs), validating the target specificity of the method.
  • Seer's approach provides customers with unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.
  • “At Seer, we offer researchers a new method for pQTL mapping and a deeper understanding of proteins and peptides for large-scale proteogenomic studies.”